Movano Health faces Nasdaq delisting threat as bid price and filing delays breach compliance rules

Movano Health (Nasdaq: MOVE), a wearable-focused health technology developer, has received a formal delisting notice from The Nasdaq Capital Market following non-compliance with the minimum bid price rule and failure to timely file its Q1 2025 Form 10-Q. In response, the California-based medtech company announced it will request a hearing before a Nasdaq Hearings Panel in an effort to remain listed while addressing regulatory concerns.

The delisting notice was issued on July 7, 2025, citing violations of Nasdaq Listing Rules 5550(a)(2) and 5250(c)(1), relating respectively to the minimum bid price requirement and timely filing of quarterly financial disclosures. The immediate consequence of this action is a 22-day stay on trading suspension, but Movano Health aims to secure an extended stay through the formal hearing process.

Why is Movano Health at risk of being delisted from the Nasdaq Capital Market at this stage of its product lifecycle?

Movano Health triggered Nasdaq’s compliance mechanism after its common stock traded below $1.00 for 30 consecutive trading sessions, violating Rule 5550(a)(2). Compounding its challenge, the company was ineligible for a customary 180-day compliance window under Rule 5810(c)(3)(A), due to a reverse stock split executed within the past 12 months. This procedural nuance restricts Nasdaq’s flexibility, placing Movano in immediate jeopardy of delisting unless relief is granted through the hearings process.

The second compliance issue arose from the late filing of Movano Health’s Form 10-Q for the fiscal quarter ending March 31, 2025. Under Rule 5250(c)(1), companies must maintain timely public disclosures of financial condition to retain listing eligibility. Together, these twin deficiencies placed the medtech innovator on a fast-track review path.

Historically, Nasdaq has applied strict scrutiny in cases where both price compliance and disclosure irregularities overlap. For small- and mid-cap issuers like Movano Health, especially those in capital-intensive healthcare verticals, such infractions often lead to heightened investor scrutiny and liquidity constraints.

What specific market pressures and historical factors contributed to Movano Health’s stock falling below the $1.00 threshold?

Movano Health has been operating in a highly competitive wearable technology sector, attempting to differentiate itself through medical-grade monitoring solutions embedded in consumer form factors. Since its 2018 founding, the California-headquartered company has launched a series of sensor-rich devices focused on chronic disease management, notably targeting women’s health and cardiovascular wellness.

However, the company’s commercial scale-up has been slower than anticipated, with market observers pointing to delays in regulatory clearances and limited early revenue traction. Over the past 12 months, Movano Health’s shares have experienced pronounced volatility, driven by dilution risk, mounting R&D expenditures, and macroeconomic headwinds affecting investor appetite for early-stage digital health platforms.

The reverse stock split completed within the past year—intended to prop up the share price and regain compliance—was an early indicator of systemic valuation challenges. But given the continued downward drift in its trading activity, the intervention proved insufficient, prompting Nasdaq to take formal action in July 2025.

How are analysts and institutional investors reacting to Movano Health’s strategy for avoiding a delisting scenario?

While no institutional investors have issued formal guidance following the July 11 announcement, investor sentiment appears cautiously pessimistic. Analysts observing the digital health space suggest that Movano Health’s decision to seek an extended stay is strategically sound in the short term, yet reflects a broader concern about its financial reporting cadence and capital market positioning.

The company’s acknowledgement that “there can be no assurance” the panel will grant an extended stay or listing exception underscores the precariousness of its Nasdaq status. Should the hearings panel reject its petition or the company fail to file its overdue 10-Q swiftly, Movano risks being relegated to the over-the-counter (OTC) markets—limiting its access to institutional funding and significantly reducing visibility with retail investors.

Industry experts note that Nasdaq has shown leniency in previous hearings when companies demonstrate a clear plan toward regaining compliance—such as concrete timelines for filings and demonstrable improvements in liquidity or capitalization. However, Movano’s lack of current eligibility for the compliance period and its ongoing disclosure lapse may weaken its position during the hearing.

What are the financial and operational implications if Movano Health fails to secure continued Nasdaq listing status?

Losing Nasdaq listing would be a critical setback for Movano Health’s ability to raise capital in public markets. Delisting could impair institutional investor confidence, reduce trading volume, and potentially trigger covenant defaults if debt instruments or investor agreements contain listing requirements.

Moreover, as a pre-revenue or low-revenue medical device platform, Movano Health is particularly dependent on equity financing to sustain product development, FDA submissions, and commercial scale-up. Transitioning to an OTC listing might dramatically limit those options, compelling management to consider bridge financing or strategic alternatives, including partnerships, licensing deals, or even M&A discussions with larger medtech players.

The firm’s forward-looking statements acknowledge the possibility of “substantial costs and diversion of personnel’s attention and resources” as it navigates the compliance process. This distraction from core operational execution may delay clinical rollouts or dampen near-term R&D velocity—challenges that are likely to ripple across the investor base.

What are the next regulatory and strategic steps for Movano Health in the hearing and compliance process?

Movano Health confirmed its intention to formally submit a hearing request to the Nasdaq Hearings Panel, along with a concurrent request for an extended stay of delisting through the conclusion of that process. While the initial stay only covers 22 calendar days from July 7, the company hopes to secure relief beyond that window—though this outcome is uncertain and subject to panel discretion.

To strengthen its case, Movano must expedite the filing of its delayed Form 10-Q and outline a compelling roadmap for restoring bid price compliance—potentially including new commercial launches, investor communications, or additional capital measures. The company could also pursue voluntary recapitalization or new investment rounds to shore up its balance sheet and improve market perception.

In its current position, success in the hearing process would buy time—but not resolution. Movano Health will remain under heightened surveillance by Nasdaq and market participants. Continued slippage in disclosures or stock performance could result in immediate delisting after the hearing.

How does Movano Health’s product positioning and market potential impact its longer-term survival despite current Nasdaq pressures?

Movano Health has built a differentiated value proposition around medical-grade, sensor-driven wearables focused on chronic conditions. The firm’s platform, spanning women’s health, cardiovascular diagnostics, and remote patient monitoring, aligns with broader trends in value-based care and preventative medicine.

With FDA clearances pending and several partnerships under discussion, Movano Health’s device suite retains strategic appeal, especially in enterprise healthcare channels. Analysts argue that if the firm can stabilize its capital structure and restore investor confidence, the long-term addressable market remains compelling.

Future viability will depend on how quickly Movano can resolve compliance issues, scale its go-to-market efforts, and demonstrate meaningful revenue progression. Institutional observers suggest that even if Nasdaq listing is lost, the firm may still find traction through private placements or strategic acquisition interest—particularly from integrated digital health platforms or diagnostic conglomerates seeking wearable expansion.